Bangalore, India, 560085
This combination tablet contains Gliclazide IP 60mg (Sustained Release) and Sitagliptin Phosphate Monohydrate IP 100mg, designed for the management of type 2 diabetes mellitus. Gliclazide SR works by stimulating insulin release from pancreatic beta cells, helping to control blood glucose levels throughout the day. Sitagliptin is a DPP-4 inhibitor that enhances incretin levels, increasing insulin release and decreasing glucagon secretion, particularly after meals. Together, this formulation provides effective glycemic control, reduces postprandial glucose spikes, and helps maintain long-term blood sugar balance. This combination is particularly beneficial for patients who require both basal and postprandial glucose control and may reduce the risk of diabetes-related complications when used alongside diet and exercise.